Immunopotentiation of Trivalent Influenza Vaccine When Given with VAX102, a Recombinant Influenza M2e Vaccine Fused to the TLR5 Ligand Flagellin

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Keipp Talbot, H ^a   Rock, Michael T ^a   Johnson, Casey ^b   Tussey, Lynda ^c   Kavita, Uma ^c   Shanker, Anita ^d   Shaw, Alan R ^c   Taylor, David N ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Johnson County Clin Trials   (United States)

^c VaxInnate Corporation   (United States)

^d Health Decisions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP B ANTIGEN; FLAGELLIN; INFLUENZA VACCINE; MATRIX PROTEIN; MATRIX PROTEIN 2; UNCLASSIFIED DRUG; VAX 102; VIRUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MONOTHERAPY; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; SKIN REDNESS; SWEATING;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; FEMALE; FLAGELLIN; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIGANDS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; TOLL-LIKE RECEPTOR 5;

ORTHOMYXOVIRIDAE; SALMONELLA TYPHIMURIUM; TIPULA IRIDESCENT VIRUS;

EID: 78650827526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014442     Document Type: Article

References (13)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. Jama 289: 179-186.
2. Poland GA, Mulligan MJ (2009) The imperative of influenza vaccines for elderly individuals-an evolving story. J Infect Dis 200: 161-163.
3. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-179.
4. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64: 1375-1377.
5. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
6. Baldwin SL, Shaverdian N, Goto Y, Duthie MS, Raman VS, et al. (2009) Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27: 5956-5963.
7. Goodwin K, Viboud C, Simonsen L (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
8. Kendal AP, Pereira MS, Skehel JJ, eds (1982) Concepts and Procedures for Laboratory-Based Influenza Surveillance. Atlanta, GA: Centers for Disease Control and Prevention and Pan American Health Organization.
9. Ohigashi Y, Ma C, Jing X, Balannick V, Pinto LH, et al. (2009) An amantadinesensitive chimeric BM2 ion channel of influenza B virus has implications for the mechanism of drug inhibition. Proc Natl Acad Sci U S A 106: 18775-18779.
10. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ (2009) Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 200: 172-180.
11. Cherry James ÂD, Chang SJ, Klein D, Lee M, Barenkamp S, et al. (2004) Prevalence of Antibody to Bordetella pertussis Antigens in Serum Specimens Obtained from 1793 Adolescents and Adults. Clinical Infectious Diseases 39: 1715-1718.
12. Fan J, Liang X, Horton MS, Perry HC, Citron MP, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
13. Black S, Kushner I, Samols D (2004) C-reactive Protein. J Biol Chem 279: 48487-48490.